# Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

> **NCT03063086** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 116 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** QVM149 150/50/80 μg o.d.
- **DRUG:** QVM149 150/50/160 μg o.d.
- **DRUG:** salmeterol/fluticasone FDC 50/500 μg b.i.d.

## Key facts

- **NCT ID:** NCT03063086
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-21
- **Primary completion:** 2018-08-02
- **Final completion:** 2018-08-02
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2021-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03063086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03063086, "Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03063086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*